Journal of Toxicology / 2012 / Article / Tab 2 / Clinical Study
Application of Purified Botulinum Type A Neurotoxin to Treat Experimental Trigeminal Neuropathy in Rats and Patients with Urinary Incontinence and Prostatic Hyperplasia Table 2 BPH Patient profiles and results after intraprostatic NTX treatment.
Baseline 1 week 1 month 3 months 6 months 9 months 12 months Number of patients 10 10 10 10 9 9 8 IPSS 23.8 ± 7.0 19.4 ± 9.3* 16.3 ± 10.3* 14.9 ± 8.2* 13.8 ± 7.5* 13.8 ± 7.6* 16.9 ± 7.3* Storage 8.7 ± 4.8 7.2 ± 4.5 6.7 ± 5.4 5.3 ± 3.8* 4.4 ± 3.5* 5.4 ± 3.5* 5.2 ± 4.3* Voiding 11.8 ± 3.4 9.5 ± 4.4 6.9 ± 5.0* 7.4 ± 4.8* 7.0 ± 4.2* 6.8 ± 4.5* 7.4 ± 4.6* QOL score 5.2 ± 1.0 4.3 ± 1.6* 3.4 ± 1.6* 3.3 ± 1.8* 3.2 ± 1.6* 3.7 ± 1.4* 4.3 ± 1.5* Qmax, mL/s 6.3 ± 3.1 5.5 ± 2.0 6.1 ± 2.6 8.8 ± 2.9* 6.8 ± 3.9 6.2 ± 2.2 7.2 ± 4.0 Residual urine (mL) 99.5 ± 94.5 84.9 ± 83.1 101.5 ± 97.0 65.3 ± 73.6* 52.9 ± 62.5* 86.3 ± 100 72.4 ± 58.2 Prostatic volume (mL) 47.8 ± 21.2 45.9 ± 22.3 40.2 ± 18.2* 39.2 ± 19.5* 40.2 ± 19.2* 42.9 ± 23.2 41.0 ± 17.0 PSA (ng/mL) 4.30 ± 3.0 3.75 ± 2.2 4.35 ± 2.8
*Compared with baseline,
𝑃
<
0
.
0
5
.